Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock between February 9 and 13, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Company Background and Allegations - Metagenomi, described as a "genetic medicines company," had a collaboration with Moderna, which was highlighted during its IPO [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at $15 per share [4] - The collaboration with Moderna was terminated on May 1, 2024, leading to claims that investors suffered damages when the true details were revealed [4]
MGX DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGX